Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020).
Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020).
复制标题
DOI：
10.1183/16000617.0287-2020
复制
发表时间：
2020-09-30
期刊：
影响因子：
--
通讯作者：
Wilson KC
中科院分区：
文献类型：
--
作者：
Bai C;Chotirmall SH;Rello J;Alba GA;Ginns LC;Krishnan JA;Rogers R;Bendstrup E;Burgel PR;Chalmers JD;Chua A;Crothers KA;Duggal A;Kim YW;Laffey JG;Luna CM;Niederman MS;Raghu G;Ramirez JA;Riera J;Roca O;Tamae-Kakazu M;Torres A;Watkins RR;Barrecheguren M;Belliato M;Chami HA;Chen R;Cortes-Puentes GA;Delacruz C;Hayes MM;Heunks LMA;Holets SR;Hough CL;Jagpal S;Jeon K;Johkoh T;Lee MM;Liebler J;McElvaney GN;Moskowitz A;Oeckler RA;Ojanguren I;O'Regan A;Pletz MW;Rhee CK;Schultz MJ;Storti E;Strange C;Thomson CC;Torriani FJ;Wang X;Wuyts W;Xu T;Yang D;Zhang Z;Wilson KC
2019 年冠状病毒病（COVID-19）是由严重急性呼吸系统综合症冠状病毒 2 引起的疾病。共识建议可以标准化护理，从而改善结果并促进未来的研究。成立了一个国际工作组，并使用建议和证据意见趋同（CORE）流程来衡量有关行动方案的一致意见。需要70%的同意才能提出共识建议。工作组就使用瑞德西韦和地塞米松治疗急性 COVID-19 肺炎患者达成共识，但建议除临床试验外不要使用羟氯喹；这些是对临时发表的几项随机试验得出的先前建议的修订。它还建议患有静脉血栓栓塞事件的 COVID-19 患者接受为期 3 个月的治疗性抗凝治疗。工作组未能达成足够的一致意见，无法就 COVID-19 幸存者的出院后护理提出共识建议。该工作组以一票之差未能建议对抑郁症、焦虑症和创伤后应激障碍进行常规筛查。该工作组解决了与 COVID-19 患者的药物治疗和幸存者的出院后护理相关的问题，并提出了几项共识建议。没有足够一致意见来制定建议的管理选项代表了研究重点。对于需要氧气支持的急性 COVID-19 肺炎患者，国际工作组建议使用瑞德西韦和地塞米松，但反对羟氯喹。 COVID-19 幸存者的出院后管理是研究的重点。 https://bit.ly/32B96uI
Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome-coronavirus-2. Consensus suggestions can standardise care, thereby improving outcomes and facilitating future research. An International Task Force was composed and agreement regarding courses of action was measured using the Convergence of Opinion on Recommendations and Evidence (CORE) process. 70% agreement was necessary to make a consensus suggestion. The Task Force made consensus suggestions to treat patients with acute COVID-19 pneumonia with remdesivir and dexamethasone but suggested against hydroxychloroquine except in the context of a clinical trial; these are revisions of prior suggestions resulting from the interim publication of several randomised trials. It also suggested that COVID-19 patients with a venous thromboembolic event be treated with therapeutic anticoagulant therapy for 3 months. The Task Force was unable to reach sufficient agreement to yield consensus suggestions for the post-hospital care of COVID-19 survivors. The Task Force fell one vote shy of suggesting routine screening for depression, anxiety and post-traumatic stress disorder. The Task Force addressed questions related to pharmacotherapy in patients with COVID-19 and the post-hospital care of survivors, yielding several consensus suggestions. Management options for which there is insufficient agreement to formulate a suggestion represent research priorities. For patients with acute COVID-19 pneumonia who require oxygen support, the International Task Force made suggestions for remdesivir and dexamethasone, but against hydroxychloroquine. Post-discharge management of COVID-19 survivors is a research priority. https://bit.ly/32B96uI
登录
查看更多内容
影响因子：
8.3
作者：
Gandotr, Sheetal;Lovato, James;Morris, Peter E.
通讯作者：
Morris, Peter E.
影响因子：
158.5
作者：
Cavalcanti, A. B.;Zampieri, F. G.;Berwanger, O.
通讯作者：
Berwanger, O.
影响因子：
158.5
作者：
Ackermann, Maximilian;Verleden, Stijn E.;Jonigk, Danny
通讯作者：
Jonigk, Danny
影响因子：
158.5
作者：
Herridge, Margaret S.;Tansey, Catherine M.;Cheung, Angela M.
通讯作者：
Cheung, Angela M.
DOI：
10.15585/mmwr.mm6912e2
发表时间：
2020-03-27
期刊：
MMWR. Morbidity and mortality weekly report
影响因子：
--
作者：
CDC COVID-19 Response Team
通讯作者：
CDC COVID-19 Response Team